News & Updates

Patients with rheumatoid arthritis (RA) also suffer several comorbidities, the most common being circulatory and metabolic disorders, according to a Bangladesh study.

The novel small-protein IL-17 inhibitor izokibep demonstrates durable efficacy and a favourable safety profile over 52 weeks in patients with active psoriatic arthritis (PsA), with sustained improvements in joint, skin, and quality-of-life outcomes in a phase IIB/III study.

Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint.